Fingers crossed as Bydureon resubmitted in the US
This article was originally published in Scrip
Executive Summary
As expected, Amylin Pharmaceuticals, Lilly and Alkermes have submitted their reply to a complete response letter issued last year by the US FDA regarding Bydureon (exenatide extended-release for injectable suspension) for type 2 diabetes.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.